Dendritic cell vaccines
Vaccines made from a patient's own antigen-presenting cells loaded with tumour proteins; sipuleucel-T for prostate cancer was the first approved, and newer versions are tested in brain and other cancers.
Overview
Dendritic cells present antigens to T cells. Sipuleucel-T, approved in 2010 for metastatic castration-resistant prostate cancer, loads the patient's antigen-presenting cells with a prostatic acid phosphatase fusion protein and reinfuses them, prolonging survival modestly. Later dendritic cell vaccines pulsed with tumour lysate or RNA have reached phase 3 in glioblastoma and are combined with checkpoint inhibitors, while off-the-shelf approaches try to target dendritic cells inside the body.
How it works
Leukapheresis harvests monocytes, which are matured into dendritic cells, loaded with antigen and reinfused to prime tumour-specific T cells.
- Proven survival benefit in prostate cancer
- Personalised, low toxicity
- Costly, individual manufacturing
- Modest response rates as single agents
Latest papers
topQuery for this technology: (TITLE:"Dendritic cell vaccines" OR ABSTRACT:"Dendritic cell vaccines") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Dendritic cell vaccines, not a curated reading list.
Similar pages
not linked directly; found by shared links- CompanyDendreon
Shares Sipuleucel-T, Prostate cancer.